Slide 1: 2022 Full Year results
2022 Full Year results 27 April 2023 141
Slide 2: Disclaimer
Disclaimer The document attached hereto and the presentation of which it forms part (together the “Materials”) have been prepared by Novacyt S.A. (“Novacyt” or the “Company”). The Materials are confidential and personal to you and are furnished to you as background information to provide a basis for
Slide 3: Presenters
Presenters • Acting CEO since November 2022 • Appointed CFO of Novacyt in 2021 • Joined Novacyt in 2017 • Over 30 years in international manufacturing • Group Finance Director since February 2020 and industrial businesses in both consumer • Over 12 years in financial management at a and B2B globally
Slide 4: Building a leading global clinical diagnostics company
Building a leading global clinical diagnostics company Our vision Committed to becoming a leading, global clinical diagnostics company in infectious diseases Company capabilities Our purpose We protect lives from invisible threats by enabling informed clinical decision-making through quality diagnos
Slide 5: 2022 a year of transition
2022 a year of transition • Internal development of Gi • Solid commercial progress with bacterial, Gi Viral and Winterplex plus international launch of Winterplex and external access to >40 clinical ID new development contracts assays • Successful expansion of RUO • Business Development continues to
Slide 6: 2022 Audited – Income statement
2022 Audited – Income statement Continuing operations * 2022 2021 £'000 £'000 Revenue 21,040 92,603 • Group revenue totalled £21.0m, in line with guidance, (2021: £92.6m), Gross profit ** 5,746 28,226 due to the expected decline in COVID-19 related sales Gross profit % 27% 30% OPEX (19,286) (25,131)
Slide 7: 2022 Audited – Statement of financial position
2022 Audited – Statement of financial position Dec-22 Dec-21 Dec-22 Dec-21 £'000 £'000 £'000 £'000 Share capital and • Cash position was £87.0m (2021: £101.7m). The Company Goodwill 6,646 11,471 premium 54,633 54,646 remains debt free Retained earnings and Right-of-use assets 521 1,788 reserves 60,5
Slide 8: Delivery against strategy
Delivery against strategy 8
Slide 9: Building a sustainable growth business, serving high unmet needs in infectious diseases
Building a sustainable growth business, serving high unmet needs in infectious diseases 2021 ~2026 80% COVID-19 revenues < 10% COVID-19 revenues Transition 20% non-COVID-19 revenues > 90% non-COVID-19 revenues Four Strategic Pillars Portfolio Geographic Business Instrumentation development expansion
Slide 10: Developing new products and workflow solutions
Developing new products and workflow solutions Portfolio development • Building in-house IVDR pipeline, initially with launch of genesig™ Winterplex and plans for up to 10 more assays in 2023, initially as RUO multiplex products • Launched a portfolio of CE marked clinical assays in STI, GI and resp
Slide 11: Commercialising and accelerating the strategy
Commercialising and accelerating the strategy Geographic Expansion • Commercialised Winterplex panel with sales to hospitals in both the UK and Europe • Gaining traction in RUO with salmon farming in North America and partnering leading global non- governmental organisation (NGO) to support the dete
Slide 12: Positioning the business for long-term sustainable growth
Positioning the business for long-term sustainable growth ▪ Over the last year we implemented a number of strategic changes to build on the strength of the core business and transition beyond COVID-19: ▪ Accelerating the development of a relevant post-COVID portfolio both internally and with externa
Slide 13: Building a leading global clinical diagnostics company
Building a leading global clinical diagnostics company Our vision Committed to becoming a leading, global clinical diagnostics company in infectious diseases Company capabilities Our purpose We protect lives from invisible threats by enabling informed clinical decision-making through quality diagnos
Slide 14: info@novacyt.com novacyt.com Novacyt Group (UK)
info@novacyt.com novacyt.com Novacyt Group (UK) York House, School Lane, Chandlers Ford, Eastleigh, SO53 4DG, UK T +44 (0)2380 748 830 14